pp-229 Tablets
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Focal Segmental Glomerulosclerosis (FSGS) / Clinical stage: Phase 3 / Modality: Small molecule CCR2 chemokine receptor antagonist / Mechanism & Target: CCR2 antagonist inhibiting immune infiltration / Route & form: Oral / Differentiation: First-in-class for FSGS; FDA confirmed proteinuria reduction as primary endpoint
Manufacturer #39436
| Rare disease biopharmaceutical company developing enzyme enhancement and replacement therapies. Specializes in lysosomal storage disorders and rare renal conditions with high unmet need. Expands global portfolio through strategic acquisitions and late-stage development. |
None